Congress poster: ISGE 2026 Efficacy of Elinzanetant for the Treatment of Vasomotor Symptoms Across Subgroups: a Pooled Analysis of the Phase III OASIS-1 and -2 Trials (P.397)

This post-hoc analysis evaluated elinzanetant VMS efficacy by subgroup using pooled OASIS-1 and -2 data. Mean reductions were nominally significantly greater with elinzanetant than placebo for all subgroups of BMI, smoking history, time since menopause and previous HT use as well as White and Not Hispanic/Latina subgroups. Significant differences were not seen in Black/African American or Hsipanic/Latina subgroups, but these subgroups had smaller sample sizes.